Welcome to our dedicated page for OS THERAPIES INCORPORATED SEC filings (Ticker: OSTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The OS Therapies Incorporated (OSTX) SEC filings page on Stock Titan brings together the company’s official disclosures to the U.S. Securities and Exchange Commission, offering a primary source view of its clinical-stage oncology business. As a NYSE American–listed emerging growth company, OS Therapies uses current reports on Form 8-K, registration statements, and proxy materials to describe its listeria-based cancer immunotherapy programs, ADC and drug conjugate platform, capital structure, and governance decisions.
Investors can use this page to access Form 8-K filings that detail material events such as warrant exercise inducement and exchange offers, gross proceeds from warrant exercises, and the terms of new warrants issued to accredited investors. These filings explain how OS Therapies raises capital to support regulatory submissions and commercial preparation for its lead asset OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma and to fund preparations for the proposed spin-off of its veterinary subsidiary, OS Animal Health.
Other 8-Ks and the company’s definitive proxy statement on Schedule 14A provide insight into corporate governance, including amendments to the certificate of incorporation to increase authorized common stock, changes to the 2023 Incentive Compensation Plan, quorum requirements under the bylaws, and shareholder approvals related to potential share issuances and a shareholder rights agreement. Registration statements on Form S-1 and Form S-3 describe the resale of shares underlying warrants, the company’s status as a smaller reporting company and emerging growth company, and the use of proceeds from warrant exercises.
Through Stock Titan, these filings are updated in near real time from EDGAR and are paired with AI-powered summaries that translate legal and financial language into plain English. Users can quickly understand the key points of complex documents, such as how a warrant inducement affects dilution, what changes a bylaw amendment introduces, or how a registration statement relates to existing warrants. Over time, this filings archive helps investors follow OS Therapies’ progress as it advances OST-HER2 through the regulatory process, develops its tunable ADC (tADC) platform, and executes on planned transactions like the OS Animal Health spin-off.
OS Therapies Incorporated entered into a private placement on March 4, 2026, issuing 10.0% original issue discount unsecured convertible promissory notes and accompanying warrants to accredited investors for aggregate gross cash proceeds of $2,000,000.
The notes have an aggregate principal amount of $2,200,000, bear 4% annual interest, and mature on March 4, 2027, with both principal and accrued interest convertible into equity under mandatory and voluntary conversion features, including a 10‑day volume‑weighted price discount mechanism and anti‑dilution adjustments.
Investors also received warrants to purchase up to 1,666,667 common shares at an exercise price of $1.40 per share, based on an average prior trading price of $1.32, with 4.99% or 9.99% ownership caps and a 19.99% overall issuance limit unless stockholders approve more. Net proceeds are earmarked for clinical development, research and development, and general corporate purposes, and the company agreed to restrictive debt covenants, limitations on variable‑price financings, and to register the underlying shares for resale on a Form S‑3 or Form S‑1.
McKean-Dieser Avril Suzette reported acquisition or exercise transactions in a Form 4 filing for OSTX. The filing lists transactions totaling 50,000 shares. Following the reported transactions, holdings were 50,000 shares.
Search Theodore F. reported acquisition or exercise transactions in a Form 4 filing for OSTX. The filing lists transactions totaling 50,000 shares. Following the reported transactions, holdings were 50,000 shares.
Ciccio John reported acquisition or exercise transactions in a Form 4 filing for OSTX. The filing lists transactions totaling 50,000 shares. Following the reported transactions, holdings were 50,000 shares.
Acevedo Christopher P. reported acquisition or exercise transactions in a Form 4 filing for OSTX. The filing lists transactions totaling 100,000 shares. Following the reported transactions, holdings were 100,000 shares.
PETIT ROBERT reported acquisition or exercise transactions in a Form 4 filing for OSTX. The filing lists transactions totaling 100,000 shares. Following the reported transactions, holdings were 100,000 shares.
Romness Paul A. reported acquisition or exercise transactions in a Form 4 filing for OSTX. The filing lists transactions totaling 1,000,000 shares. Following the reported transactions, holdings were 1,000,000 shares.
Jarry Olivier Roger reported acquisition or exercise transactions in a Form 4 filing for OSTX. The filing lists transactions totaling 50,000 shares. Following the reported transactions, holdings were 50,000 shares.
Galzahr Karim reported acquisition or exercise transactions in a Form 4 filing for OSTX. The filing lists transactions totaling 50,000 shares. Following the reported transactions, holdings were 50,000 shares.
OS Therapies President and CEO Paul A. Romness reported an amended insider transaction reflecting a grant of 1,000,000 stock options on October 21, 2025. The options have an exercise price of $1.8 per share, are fully vested on the one-year anniversary of the grant date, and expire on October 21, 2035, assuming continued employment on the vesting date. Following this award, Romness beneficially owned 2,473,000 shares of common stock directly. The amendment corrects an earlier filing that had misreported the number of shares underlying this stock option grant.